Company profile

Cadence

Chronic Disease Management & Digital Therapeutics

Company profile

About Cadence

Cadence is a clinical AI company that automates chronic disease management for health systems, payers, and medical groups. The company's Clinical Intelligence platform combines AI agents with a multidisciplinary care team to provide continuous monitoring, medication titration, and proactive intervention for patients with chronic conditions between clinical visits. Cadence's technology integrates directly into existing EMR workflows, enabling physicians to manage larger patient panels without additional burden. The platform tracks vitals, symptoms, medications, and engagement data, using AI to flag risks early and automate protocol-driven decisions while keeping physicians in control. Cadence offers three primary care models: 24/7 Preventive Primary Care (a Medicare-covered model for PCPs), Remote Patient Care (daily vitals monitoring and treatment), and Post-Acute Care (post-discharge support). The company is trusted by over 20 health systems and has enrolled more than 85,000 patients. Cadence's approach has demonstrated peer-reviewed clinical outcomes including a $1,302 decrease in total cost of care per patient per year, 27% reduction in hospital admissions, and significant improvements in blood pressure control and medication adherence. The company is on a mission to deliver life-changing treatment to 1 million people with chronic conditions by the end of the decade.

Company description Cadence official website

Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Cadence?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • chronic diseases
  • heart failure
  • hypertension
  • post-acute care
  • stroke
  • type 2 diabetes

Who it serves

  • Clinicians
  • Health Systems
  • Medical groups
  • Payers

Deployment & integration

Deployment information is currently being developed.

Geographic context

Marketsrural and underserved areas · United States
Company sourceOfficial website

Company milestones

Platform expansion

$100M Series C funding led by Spark Capital (June 2026), CMS ACCESS Model participation confirmed (March 2026), launched AI-powered Proactive Care Engine (July 2025), named to 2024 LinkedIn Top Startups List, multiple health system partnerships announced 2025-2026

Partnerships

Recorded partners

  • Community Health Systems
  • Duke Health
  • Hackensack Meridian Health
  • Hartford HealthCare
  • Mayo Clinic
  • Memorial Hermann
  • Providence
  • Texas Health Resources

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

No source-backed Company products are currently listed.

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

Research

Publications & preprints

Impact of a Nationwide Remote Patient Care Hypertension Program on Clinical and Health Care Cost and Utilization Outcomes.

Mayo Clinic proceedings · Aug 27, 2026

Coalescence of suspended and sessile isotropic and radial nematic liquid crystal drops.

Soft matter · Aug 4, 2026

AlphaGo-driven generative machine learning framework for inverse topology synthesis and optimization of planar antennas.

Scientific reports · Jul 9, 2026

A computational analysis of the glycoprotein LRP1 structure and the role of glycans as quaternary glue.

Bioinformatics (Oxford, England) · Jun 4, 2026

Kainic acid pig model of hippocampal epilepsy.

Scientific reports · Jun 4, 2026

Epicardial adipose tissue signatures in Asian coronary artery disease: Insights from cardiac CT.

American journal of preventive cardiology · Jun 1, 2026

Clinical validation

Clinical-trial records

Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients

NCT06975059 · Mentioned · SUSPENDED

Training and Testing Database for IMU Based Gait Analysis Methods

NCT07236008 · Mentioned · RECRUITING

Adaptive Self-Efficacy-Based AI Coaching for Cycling

NCT07318233 · Mentioned · RECRUITING

Rehabilitation Assessment of Motor Function In Cerebral Palsy Using Explainable AI

NCT07629024 · Mentioned · NOT YET RECRUITING

Gait Analysis in Neurological Disease

NCT02994719 · Mentioned · ACTIVE NOT RECRUITING

Inspiring Seniors Towards Exercise Promotion - 2

NCT07629739 · Mentioned · RECRUITING

Regulatory

Regulatory records

No linked records are currently available.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

$1,302 decrease in total cost of care per patient per year

Mayo Clinic Proceedings study, February 2026

27% reduction in hospital admissions

Mayo Clinic Proceedings study

$1,428 decrease in inpatient spend per patient per year

Mayo Clinic Proceedings study

8.4 day reduction in length of hospital stay for stroke patients

Mayo Clinic Proceedings study

$203 monthly cost savings per patient

NEJM Catalyst, October 2025

43% increase in blood pressure control

NEJM Catalyst study

4.9/5 patient satisfaction with NPS of +40

NEJM Catalyst study

$1,077 monthly cost savings per heart failure patient

Journal of Cardiac Failure, September 2024

7/5 mmHg average blood pressure reduction

JACC Advances, July 2025

18% decrease in hospital admissions

Heart failure study, November 2025

$183 monthly cost savings

Heart failure study across 1,786 patients

85K clinician hours returned to the system annually

2025 operations

24K medication titrations in 2025

2025 operations

99% alerts resolved without physician escalation

2025 operations

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from Cadence

Recent articles published on Cadence's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Chronic Disease Management & Digital Therapeutics

Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon